-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 29, the website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) showed that China’s first original antibody-conjugated drug (ADC) new drug, vedixituzumab ("injectable Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent") was officially included in the breakthrough treatment category, and the indications are HER2-positive advanced breast cancer patients with liver metastases who have been treated with trastuzumab and taxanes in the past